Metagenics® Ceralin®: The Pharmacist's Guide to Neurological Health & B Vitamin Support

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Nervous System’s Nutritional Demands

The brain and nervous system are among the most metabolically active tissues in the body, consuming approximately 20% of total energy despite representing only 2% of body weight. This extraordinary metabolic demand makes the nervous system uniquely vulnerable to nutritional deficiencies — particularly deficiencies in B vitamins, which serve as essential cofactors in virtually every aspect of neurological function.

Metagenics® Ceralin® is a practitioner-grade neurological support formula providing a full B-vitamin complex alongside N-acetylcysteine (NAC), acetyl-L-carnitine (ALCAR), and grape seed extract. This article focuses primarily on the B-vitamin evidence base; the additional ingredients are noted in the Supplement Facts section below.

Supplement Facts (Per 3-Capsule Serving)

**Daily Value not established. †As Metafolin®, registered trademark of Merck KGaA. Serving size: 3 capsules. Servings per container: 30.

Directions & Safety

Per the current manufacturer label, take three capsules daily or as directed by a healthcare practitioner. Do not use if pregnant or nursing. Consult your healthcare practitioner before use if you have a history of kidney stones or seizures, or if you take medications. Maintain adequate fluid intake. Because Ceralin® provides 25 mg of vitamin B6 per serving, total supplemental B6 exposure should also be considered, particularly in patients with unexplained sensory neuropathy.

Key Nutrients and Their Neurological Roles

Thiamine (Vitamin B1) — 30 mg

Thiamine is indispensable for glucose metabolism in the brain — the primary fuel source for neurons. Thiamine deficiency causes Wernicke’s encephalopathy, characterized by confusion, ataxia, and ophthalmoplegia. Even subclinical insufficiency is associated with cognitive impairment, peripheral neuropathy, and fatigue.

Riboflavin (Vitamin B2) — 30 mg

Riboflavin is a cofactor for flavoenzymes involved in mitochondrial energy production and antioxidant defense in neural tissue. A landmark RCT (Schoenen et al., PMID: 9484373) found that riboflavin 400 mg/day for 3 months significantly reduced migraine attack frequency and headache days — with 59% of riboflavin-treated participants vs. 15% of placebo recipients achieving at least 50% improvement in headache days. Important: Ceralin® provides 30 mg riboflavin per serving — approximately 13× lower than the trial dose. Migraine-prophylaxis findings from that trial cannot be assumed to apply to Ceralin® at its current dose.

Niacin (Vitamin B3) — 250 mg

Niacin is a precursor to NAD+, the coenzyme central to cellular energy production and DNA repair. In the nervous system, NAD+ supports neuronal survival, axonal integrity, and protection against neurodegeneration.

Vitamin B6 (as Pyridoxine HCl) — 25 mg

Vitamin B6 is required for synthesis of serotonin, dopamine, GABA, and norepinephrine, and is essential for homocysteine metabolism. B6 safety note: Both inadequate and excessive vitamin B6 exposure warrant consideration in patients with neuropathic symptoms. A systematic review of 20 studies (PMID: 37447150) found that high B6 levels — typically supplement-associated — may produce predominantly sensory axonal neuropathy, and did not establish a therapeutic role for B6 supplementation in peripheral neuropathy. Ceralin® provides 25 mg B6 per serving (1,250% DV). Patients should consider their total B6 exposure across all supplements rather than assuming higher intake is beneficial.

Folate (as 5-MTHF, Metafolin®) — 830 mcg DFE

Ceralin® provides folate as 5-methyltetrahydrofolate (5-MTHF), the predominant circulating biologically active folate form. The common MTHFR C677T variant can influence folate status and homocysteine metabolism, particularly in individuals homozygous for the 677T allele. However, people with MTHFR variants are still capable of responding to folic acid supplementation; the presence of a common MTHFR variant alone does not establish a clinical requirement for 5-MTHF over folic acid. Folate is essential for myelin synthesis, neurotransmitter production, and homocysteine remethylation.

Vitamin B12 (as Methylcobalamin) — 500 mcg

Methylcobalamin is the neurologically active form of B12, essential for myelin sheath maintenance, nerve conduction, and DNA synthesis. B12 deficiency — increasingly common in older adults, vegetarians, and those on long-term metformin or proton-pump inhibitor therapy — can cause subacute combined degeneration of the spinal cord, peripheral neuropathy, and cognitive decline.

Metformin and B12: Long-term metformin therapy is associated with reduced vitamin B12 concentrations and increased risk of biochemical B12 deficiency. A 4.3-year randomized trial (de Jager et al., PMID: 20488910) found metformin produced a mean 19% decrease in B12 and increased the absolute risk of B12 deficiency by 7.2 percentage points versus placebo. A long-term DPP/DPPOS follow-up analysis (Aroda et al., PMID: 26900641) found each additional year of metformin use was associated with increased odds of B12 deficiency (OR 1.13/year). Patients receiving long-term metformin — particularly those with anemia, neuropathy, or other risk factors — may benefit from periodic B12 assessment and appropriate supplementation when deficiency or insufficiency is identified.

PPIs and B12: Long-term proton-pump inhibitor use has been associated with a modestly increased risk of vitamin B12 deficiency in observational evidence, although results across studies are heterogeneous (Choudhury et al., PMID: 37060552; pooled OR 1.42 across 25 studies, with substantial heterogeneity; authors considered the association insufficiently clear to establish PPIs as definite B12 depletors). B12 assessment may be reasonable when additional risk factors, symptoms, or prolonged therapy are present.

Additional Ingredients: NAC, ALCAR, Grape Seed Extract

Each serving also provides N-acetylcysteine (600 mg), a glutathione precursor with antioxidant and neuroprotective properties; acetyl-L-carnitine (600 mg), which supports mitochondrial fatty acid metabolism and acetylcholine synthesis; and grape seed extract (204 mg, standardized to 85% [170 mg] polyphenols), a broad-spectrum antioxidant. The evidence for these ingredients is not reviewed in depth in this article; their inclusion meaningfully expands Ceralin®’s formulation beyond a standard B-complex.

The Clinical Evidence

• Mild cognitive impairment / brain atrophy: In the VITACOG trial (PMID: 20838622), high-dose folic acid, B6, and B12 significantly slowed brain atrophy in older adults with mild cognitive impairment over 2 years. The effect was greatest among participants with elevated baseline homocysteine; in those with homocysteine >13 μmol/L, the rate of brain atrophy was approximately 53% lower than placebo. This was a subgroup finding and should not be generalized as the overall treatment effect. Trial doses: folic acid 0.8 mg/day + B12 0.5 mg/day + B6 20 mg/day.
• Migraine prevention: Riboflavin 400 mg/day significantly reduced migraine attack frequency and headache days in a 55-person RCT (PMID: 9484373). Ceralin® provides 30 mg riboflavin — approximately 13× lower than the trial dose. Efficacy findings cannot be assumed to apply at this dose.
• Diabetic peripheral neuropathy: A systematic review of seven randomized trials (PMID: 16008162) found B12-containing combinations and methylcobalamin showed improvement in some neuropathic symptoms (particularly pain and paresthesia), while effects on electrophysiologic measures were inconsistent and most trials were low quality. A subsequent 1-year RCT in metformin-treated patients with low B12 and diabetic neuropathy (Didangelos et al., PMID: 33513879) found multiple neurophysiologic and symptom measures improved with methylcobalamin 1,000 μg/day vs. placebo. Ceralin® provides 500 mcg methylcobalamin — half the trial dose. Findings cannot be assumed to apply at this dose.
• B6 and peripheral neuropathy — safety: A systematic review of 20 studies (PMID: 37447150) found high supplemental B6 may cause predominantly sensory axonal neuropathy and did not establish a therapeutic role for B6 in peripheral neuropathy. Ceralin® provides 25 mg B6 per serving; total daily B6 exposure from all sources should be considered.
• MTHFR and folate response: A meta-analysis of folate-intervention studies (PMID: 26497154) found MTHFR 677TT was associated with higher homocysteine and lower serum folate at baseline, but folic acid supplementation still improved folate and homocysteine measures across genotypes. Presence of a common MTHFR variant does not establish inability to respond to folic acid.

Who Should Consider Ceralin®?

• Older adults at increased risk of vitamin B12 insufficiency or impaired B12 absorption
• Patients on long-term metformin with documented or suspected B12 insufficiency
• Those on long-term PPI therapy with additional B12 deficiency risk factors
• Vegetarians and vegans at risk of B12 deficiency
• Individuals with MTHFR C677T homozygosity with suboptimal folate or elevated homocysteine
• Migraine sufferers seeking evidence-based riboflavin prophylaxis — note: the evidence-based riboflavin dose (400 mg/day) substantially exceeds Ceralin®’s riboflavin content; discuss with your pharmacist or physician
• Individuals with peripheral neuropathy or cognitive concerns being evaluated for B vitamin status

Pharmacist’s Note

As a PharmD, I recommend Ceralin® most confidently for patients with documented or high-risk B vitamin insufficiency — particularly those on long-term metformin, older adults with increased risk of impaired B12 absorption, and individuals with confirmed MTHFR C677T homozygosity and suboptimal folate status. The formula’s inclusion of NAC, ALCAR, and grape seed extract meaningfully expands its scope beyond a standard B-complex, though those ingredients are not the primary focus of this review. Patients should be aware that the riboflavin dose (30 mg) and B12 dose (500 mcg) in Ceralin® are lower than the doses used in the key migraine and diabetic neuropathy trials, respectively. I discuss Ceralin® as part of a comprehensive nutritional and clinical assessment — not as a standalone treatment for any neurological condition. Free PharmD consultation: (408) 622-8068.

Please consult your pharmacist or physician before use, especially if you are taking medications that affect B vitamin metabolism or if you have a neurological condition under active management.

Selected Key Studies

1. HUMAN RCT Smith AD, Smith SM, de Jager CA, et al. Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial (VITACOG). PLoS ONE. 2010;5(9):e12244. PMID: 20838622. DOI: 10.1371/journal.pone.0012244.
   n=168, 24 months; folic acid 0.8 mg/day + B12 0.5 mg/day + B6 20 mg/day vs. placebo in older adults with MCI. High-dose B vitamins significantly slowed brain atrophy overall. In the subgroup with baseline homocysteine >13 μmol/L, the rate of brain atrophy was approximately 53% lower than placebo — a subgroup result, not the overall treatment effect. Does not establish reversal of established dementia.
2. HUMAN RCT Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50(2):466–470. PMID: 9484373. DOI: 10.1212/WNL.50.2.466.
   n=55; riboflavin 400 mg/day for 3 months. Significantly reduced migraine attack frequency and headache days vs. placebo. 59% of riboflavin recipients vs. 15% of placebo achieved ≥50% improvement in headache days. Ceralin® provides 30 mg riboflavin — approximately 13× lower than the trial dose. Efficacy at this dose cannot be assumed.
3. SYSTEMATIC REVIEW Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan. 2005;14(2):48–54. PMID: 16008162.
   Seven randomized trials reviewed. B12-containing combinations and methylcobalamin showed improvement in some neuropathic symptoms (particularly pain and paresthesia). Effects on vibration perception and electrophysiologic measures were inconsistent. Most included trials were of limited methodological quality.
4. HUMAN RCT Didangelos T, Karlafti E, Kotzakioulafi E, et al. Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2021;13(2):395. PMID: 33513879. DOI: 10.3390/nu13020395.
   n=90 metformin-treated adults with diabetic neuropathy and B12 <400 pmol/L; methylcobalamin 1,000 μg/day vs. placebo for 1 year. Multiple neurophysiologic and symptom measures improved vs. placebo. Ceralin® provides 500 mcg methylcobalamin — half the trial dose. Does not establish that B12 treats all forms of peripheral neuropathy.
5. HUMAN RCT de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181. PMID: 20488910. DOI: 10.1136/bmj.c2181.
   n=390; metformin vs. placebo over 4.3 years. Metformin produced a mean 19% decrease in B12 and increased absolute risk of B12 deficiency by 7.2 percentage points. Supports periodic B12 monitoring in long-term metformin users.
6. LONG-TERM HUMAN FOLLOW-UP Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. PMID: 26900641. DOI: 10.1210/jc.2015-3754.
   Long-term DPP/DPPOS follow-up analysis; each year of metformin use associated with increased odds of biochemical B12 deficiency (OR 1.13/year). Directionally consistent with the de Jager RCT. Secondary analysis; confounding cannot be fully excluded.
7. META-ANALYSIS Colson NJ, Naug HL, Nikbakht E, Zhang P, McCormack J. The impact of MTHFR 677 C/T genotypes on folate status markers: a meta-analysis of folic acid intervention studies. Eur J Nutr. 2017;56(1):247–260. PMID: 26497154. DOI: 10.1007/s00394-015-1076-x.
   Meta-analysis of 10 folate-intervention studies. MTHFR 677TT associated with higher homocysteine and lower serum folate at baseline, but folic acid supplementation still improved folate and homocysteine measures across genotypes. Presence of a common MTHFR variant does not establish inability to respond to folic acid.
8. SYSTEMATIC REVIEW — SAFETY Muhamad R, Akrivaki A, Papagiannopoulou G, Zavridis P, Zis P. The Role of Vitamin B6 in Peripheral Neuropathy: A Systematic Review. Nutrients. 2023;15(13):2823. PMID: 37447150. DOI: 10.3390/nu15132823.
   Review of 20 studies. High B6 levels — typically supplement-associated — may produce predominantly sensory axonal neuropathy. Evidence does not establish B6 supplementation as effective monotherapy for peripheral neuropathy. Ceralin® provides 25 mg B6/serving; total daily B6 exposure from all sources should be considered.

Reviewed by: Dai Tran, PharmD, MBA, B.S.  View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com